With pressure groups and rising costs making it difficult for Western pharmaceutical firms to expand their animal testing laboratories at home, Glenn Rice has pioneered outsourcing of this work to China.
Rice, 50, is the decorous chief executive of Bridge Pharmaceuticals, a contract research organization in the San Francisco Bay area. He splits his time between there and the labs in Beijing, where scientists are cheap and plentiful and pesky protesters held at bay.
“This is a country with a large number of canines and primates, and if we establish preclinical testing facilities here, we can change the dynamics of the industry,” says Rice, who spun Bridge out of sri International in Menlo Park, California in 2004. “Animal testing also does not have the political issues it has in the U.S. or Europe or even India, where there are religious issues as well. So now big pharma is looking to move to China in a big way.”